Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Oncogenic RAS enables DNA damage- and p53-dependent differentiation of acute myeloid leukemia cells in response to chemotherapy.

PloS one - 5 Nov 2009

Meyer Mona, Rübsamen Daniela, Slany Robert, Illmer Thomas, Stabla Kathleen, Roth Petra, Stiewe Thorsten, Eilers Martin, Neubauer Andreas

Abstract excerpt

Acute myeloid leukemia (AML) is a clonal disease originating from myeloid progenitor cells with a heterogeneous genetic background. High-dose cytarabine is used as the standard consolidation chemotherapy. Oncogenic RAS mutations are frequently observed in AML, and are associated with beneficial response to cytarabine. Why AML-patients with oncogenic RAS benefit most from high-dose cytarabine post-remission...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Marrow Cells
Share to Cellular Senescence

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytarabine

Share to Daunorubicin

Share to Etoposide

Share to Genes, ras

Share to Leukemia, Myeloid, Acute

Share to ras Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 19890398
DOI: 10.1371/journal.pone.0007768
PMCID: PMC2767509

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Oncogenic RAS enables DNA damage- and p53-dependent differentiation of acute myeloid leukemia cells in response to chemotherapy.PMID 19890398Read ↗

Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR.Semantic proximity Read ↗

Clinico-genomic characterization of RAS-mutant acute myeloid leukemia.Semantic proximity Read ↗

Oncogenic N-Ras Mitigates Oxidative Stress–Induced Apoptosis of Hematopoietic Stem CellsSemantic proximity Read ↗

p53-/- synergizes with enhanced NrasG12D signaling to transform megakaryocyte-erythroid progenitors in acute myeloid leukemia.Semantic proximity Read ↗

Oncogenic NRAS Primes Primary Acute Myeloid Leukemia Cells for Differentiation.Semantic proximity Read ↗

Pharmacological or genetic inhibition of hypoxia signaling attenuates oncogenic RAS-induced cancer phenotypes.Semantic proximity Read ↗

Targeting the kinase activities of ATR and ATM exhibits antitumoral activity in mouse models of MLL -rearranged AMLSemantic proximity Read ↗

Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study.Semantic proximity Read ↗

Blocking ETV6/RUNX1-induced MDM2 overexpression by Nutlin-3 reactivates p53 signaling in childhood leukemiaSemantic proximity Read ↗

Polo-like Kinase-1, Aurora Kinase A and Wee1 Kinase Are Novel Therapeutic Targets in Chronic Myeloid LeukemiaSemantic proximity Read ↗

Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease.Semantic proximity Read ↗

Prolactin Receptor signaling induces acquisition of chemoresistance and reduces clonogenicity in Acute Myeloid LeukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.